OCT-guided PCI does not reduce target vessel failure in complex patients, but improves safety

Optical coherence tomography (OCT)-guided percutaneous coronary intervention (PCI) leads to a larger minimum stent area but does not reduce the two-year rate of target vessel failure compared with angiography-guided PCI, according to late breaking research presented in a Hot Line session today at ESC Congress 2023.

Passage Bio scraps a therapy; XOMA’s new loan; Impel is for sale

Plus, news on ImpriMed, bluebird bio and Syndax. Passage Bio shakes up its pipeline: The Jim Wilson-founded biotech is shelving a therapy for GM1 gangliosidosis.

December 21, 2023

A quick guide to transferring a commercial drug product to a new fill-finish CDMO – Pharmaceutical Technology

Between 2012 and 2021, outsourcing propensity for FDA NDA injectables approvals averaged 40%, according to GlobalData’s Contract Injectable Packaging Trends in the Bio/Pharma Industry report.

September 4, 2024

Amylyx to pull ALS drug from market, cut 70% of staff

Amylyx Pharmaceuticals will take its ALS drug Relyvrio off the market in the U.S. and Canada, ending a multi-year saga for patients with the rare

April 4, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.